Metabolic Syndrome, Inflammation, and Incident Heart Failure in the Elderly
The Cardiovascular Health Study
Takeki Suzuki, MD; Ronit Katz, DPhil; Nancy Swords Jenny, PhD; Neil A. Zakai, MD; Martin M. LeWinter, MD; Joshua I. Barzilay, MD; Mary Cushman, MD, MSc

Background—Inflammation markers and metabolic syndrome (MetS) are associated with risk of congestive heart failure (CHF). We evaluated whether combining inflammation markers and MetS provided additive information for incident CHF and if incorporating inflammation markers to the MetS definition added prognostic information.

Methods and Results—We studied 4017 men and women ≥65 years old, without baseline CHF or diabetes, participating in the Cardiovascular Health Study, an observational study with 12.2 years follow-up and 966 cases of incident CHF. Baseline “C-reactive protein (CRP)-MetS” or “interleukin (IL)-6–MetS” were defined as presence of 3 out of 6 components, with elevated CRP (≥3 mg/L) or IL-6 (≥2.21 pg/mL) as a sixth component added to ATPIII criteria. Cox models adjusted for CHF risk factors and incident coronary disease were used to calculate hazard ratios for CHF. MetS and elevated inflammation markers were independently associated with CHF risk (hazard ratios, 95% CI: 1.32, 1.16 to 1.51 for MetS; 1.53, 1.34 to 1.75 for CRP; 1.37, 1.19 to 1.55 for IL-6). There was a 20% relative excess risk attributed to the combination of MetS and CRP (95% CI, −44% to 88%). CRP-MetS and IL-6–MetS definitions reclassified 18% and 13%, respectively of participants as MetS. Both CRP-MetS and IL-6–MetS increased risk of CHF by 60% compared with those without MetS.

Conclusion—MetS and inflammation markers provided additive information on CHF risk in this elderly cohort. Inflammation-incorporated MetS definitions identified more participants with the same risk level as ATPIII MetS. Considering inflammation markers and MetS together may be useful in clinical and research settings. (Circ Heart Fail. 2008;1:242-248.)

Key Words: epidemiology  ■  heart failure  ■  metabolism  ■  inflammation

Congestive heart failure (CHF) is a major public health problem. Approximately 5 million people in the United States suffer from it and an additional half million are newly diagnosed annually.1 Although CHF occurs most often as a result of coronary heart disease (CHD), a large percentage of cases occurs in its absence.2 CHF is associated with insulin resistance independent of diabetes mellitus.3 More recently it has been recognized that inflammation factors are associated with the development and progression of CHF with and without CHD.4–13

Clinical Perspective see p 248

The metabolic syndrome (MetS) is a constellation of risk factors that cosegregate14–18 and is associated with increased cardiovascular events.17,18 Insulin resistance and inflammation are postulated among the important underlying pathophysiologies of the syndrome.19 Increased levels of inflammation markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) are observed in subjects with MetS20–22 as well as in people with components of MetS.23–26 The traditional definition of MetS incorporates measures of insulin resistance but not measures of inflammation. It has been proposed that inflammation be incorporated into the MetS definition.27

Little is known about the interrelationships between MetS, inflammation, and incident CHF at the population level. In this study, we tested the hypothesis that the combination of MetS and elevated levels of inflammation markers is associated with increased risk of CHF in the elderly. Further, we incorporated elevated CRP or IL-6 levels into the MetS definition and evaluated this modified MetS definition for its prognostic information on CHF risk.

Methods

Subjects
The Cardiovascular Health Study (CHS) is a prospective population-based observational cohort study of people ≥65 years old at baseline.
initiated to evaluate risk factors for the development and progression of cardiovascular disease. The design, rationale, and examination details have been described elsewhere.28 Briefly, participants were randomly selected from Medicare eligibility lists from 4 US field counties. An initial cohort of 5201 was recruited between 1989 and 1990 (“original cohort”) and an additional 687 blacks were recruited between 1992 and 1993 (“new cohort”). Exclusion criteria included active treatment for cancer, being wheelchair-bound or institutionalized at baseline, or inability to participate in the examination.29 Comprehensive examinations and interviews were performed annually. The study was approved by institutional review boards at each site. Informed consent was obtained from all subjects. The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.

Self-reported health behaviors, medical history, anthropometric measures, current medication use, seated blood-pressure readings, and fasting blood chemistry measures were obtained at baseline. Internal carotid intima-media thickness (IMT) was measured at baseline in a standard manner as previously described.30 All subjects in the original and new cohort were included in the present study, except for those with a baseline history of CHF (n = 275), known valvular heart disease (on the baseline questionnaire or aortic stenosis on study echocardiography, n = 65), hemodialysis or serum creatinine ≥3.5 mg/dL (n = 4), or missing values for key variables (n = 599). There were 277 missing components of MetS, 17 CRP, and 305 IL-6. Subjects with diabetes mellitus (n = 928) were excluded given our intention to examine the independent influence of MetS on CHF incidence without the confounding strong effect of diabetes mellitus on CHF.7

### Laboratory Methods
Phlebotomy was performed on the morning of enrollment after an 8- to 12-hour fast.28 Total cholesterol, high-density lipoproteins (HDL), triglycerides, glucose, insulin, and creatinine were measured at a central laboratory.31 Low-density lipoprotein cholesterol was calculated for those with triglycerides <400 mg/dL. CRP was measured by an in-house validated high-sensitivity enzyme-linked immunosorbent assay (R&D Systems, Minneapolis, Minn).32 IL-6 was measured by high-sensitivity enzyme-linked immunosorbent assay.33 The interassay coefficients of variation were 6% for CRP and 7% for IL-6.32,33 Elevated CRP was defined as ≥3 mg/L corresponding to the “high risk” category in the 2003 American Heart Association/Centers for Disease Control and Prevention consensus statement (corresponding to approximately the top 10% of the population distribution).34 CRP <3 mg/L was defined as normal in this study, corresponding to the “low to average risk” category in the American Heart Association/Centers for Disease Control and Prevention statement. Elevated IL-6 was defined as values in the top tertile of the distribution (≥2.21 pg/mL).

### Definitions
MetS was defined using the modified ATP III criteria.15 Subjects were classified as having MetS if they had 3 or more of the following 5 characteristics: 1) waist circumference ≥102 cm for men and ≥88 cm for women; 2) triglycerides ≥150 mg/dL; 3) HDL <40 mg/dL in men or <50 mg/dL in women; 4) systolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or hypertension medication use in participants with diagnosed hypertension; 5) fasting glucose >100 mg/dL or on drug treatment for elevated blood glucose. Use of fibrates and niacin/nicoitinic acid was rare (1.8%) and was not included in the definition of MetS. Because subjects with diabetes mellitus, defined as a fasting glucose of ≥126 mg/dL or the use of hypoglycemic agents or insulin, were excluded from the analysis, our definition of MetS included subjects with fasting glucose levels between 100 and 125 mg/dL. Inflammation-MetS (“CRP-MetS” or “IL-6–MetS”) was defined as 3 or more of 6 components, including elevated CRP or IL-6 as a sixth component. Baseline and incident CHD was defined as a history of myocardial infarction or a nonmyocardial infarction event, specifically, angina pectoris or a revascularization procedure (coronary artery bypass grafting or percutaneous coronary intervention).5 All cases were adjudicated by a committee that reviewed relevant medical documents.

### Adjudication of Incident CHF Events
Our outcome was incident CHF through June 30, 2005. Methods used to assess CHF events have been reported previously.35,36 Subjects were interviewed every 6 months and follow-up examinations were conducted annually at each study center until May 31, 1998, after which telephone follow-up continued. Self-report of a physician diagnosis of CHF was confirmed by review of medical records by a committee for index CHF events. Presence of CHF was determined by cardiomegaly and pulmonary edema on chest radiograph; or dilated ventricle/wall-motion abnormalities by echocardiography or contrast ventriculography; or a physician diagnosis of CHF which included administration of medical treatment (diuretic plus either digitalis, vasodilator, or angiotensin-converting enzyme inhibitor).28 Pertinent data for hospitalization or outpatient visits including history, symptoms (shortness of breath, fatigue, orthopnea, paroxysmal nocturnal dyspnea), physical signs (edema, pulmonary rales, gallop rhythm, displaced left ventricular apical impulse), chest radiograph findings, and medication use were considered.

### Statistical Analysis
Baseline characteristics were compared between those with or without MetS using χ² tests for discrete variables and t tests for continuous data. The incidence rate of CHF in groups based on MetS or inflammation status is presented as events per 1000 person-years. Cox proportional hazards models were used to examine the association of MetS, its components, and each inflammation marker with

<table>
<thead>
<tr>
<th>Table 1. Baseline Characteristics of the Cohort*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metabolic Syndrome Absent (n = 2481)</td>
</tr>
<tr>
<td>Age, y</td>
</tr>
<tr>
<td>Women, %</td>
</tr>
<tr>
<td>Black, %</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
</tr>
<tr>
<td>Waist circumference, cm</td>
</tr>
<tr>
<td>Hypertension, %</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
</tr>
<tr>
<td>Diastolic blood pressure, mm Hg</td>
</tr>
<tr>
<td>Current smoking, %</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
</tr>
<tr>
<td>Triglyceride, mg/dL</td>
</tr>
<tr>
<td>HDL, mg/dL</td>
</tr>
<tr>
<td>LDL, mg/dL</td>
</tr>
<tr>
<td>Glucose, mm/dL</td>
</tr>
<tr>
<td>CRP, mg/L†</td>
</tr>
<tr>
<td>IL-6, pg/mL†</td>
</tr>
<tr>
<td>Insulin, pmol/L†</td>
</tr>
<tr>
<td>Internal carotid IMT, mm†</td>
</tr>
</tbody>
</table>

HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; CRP, C-reactive protein; IL-6, interleukin-6; IMT, intima-media thickness.
*For continuous variables mean (SD) is shown. For categorical variables percent is shown.
†Median (IQR).
incident CHF. To control for confounding factors, the following variables were included in multivariable models: age, sex, race, field center, and cardiovascular disease risk factors (baseline CHD, low-density lipoprotein cholesterol, current smoking) and incident CHD during follow-up (time-dependent covariate). A model further adjusting for fasting insulin was used to evaluate the independent role of MetS from insulin levels, as insulin resistance is one of the underlying causes of the syndrome.19 To further account for mediation by subclinical atherosclerosis, baseline internal carotid IMT was added to the models. Kaplan-Meier curves with the end point of CHF were constructed based on inflammation status (low or elevated CRP or IL-6) and MetS status, with participants cross classified by both exposures. A log-rank test was performed to examine the difference among the four groups. To determine whether MetS and an inflammation marker increased the incidence of CHF in an additive way, hazard ratios (HR) of CHF were calculated for each group and the effect modification between MetS and inflammation was evaluated by using Rothman’s synergy index (SI).37,38 SI is the ratio of the observed effect of the joint index (SI) with the expected effect under the assumptions of no interaction (additive) or full adjustment.

Table 2. Hazard Ratios for Incident CHF by Baseline Metabolic Syndrome, Its Components, and Inflammation Status

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Incidence Rate With MetS (per 1000 Person-Years)</th>
<th>Incidence Rate Without MetS (per 1000 Person-Years)</th>
<th>Unadjusted HR (95% CI)</th>
<th>Model 1 HR* (95% CI)</th>
<th>Model 2 HR* (95% CI)</th>
<th>Model 3 HR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MetS (n=1536)</td>
<td>26.0</td>
<td>19.2</td>
<td>1.42 (1.25–1.61)</td>
<td>1.32 (1.16–1.51)</td>
<td>1.24 (1.07–1.43)</td>
<td>1.20 (1.04–1.38)</td>
</tr>
<tr>
<td>Elevated waist circumference (n=1727)</td>
<td>22.6</td>
<td>21.1</td>
<td>1.23 (1.08–1.41)</td>
<td>1.19 (1.04–1.36)</td>
<td>1.11 (0.96–1.28)</td>
<td>1.10 (0.95–1.26)</td>
</tr>
<tr>
<td>Elevated triglycerides (n=1146)</td>
<td>22.7</td>
<td>21.3</td>
<td>1.06 (0.92–1.22)</td>
<td>1.07 (0.92–1.13)</td>
<td>0.99 (0.86–1.15)</td>
<td>0.97 (0.84–1.12)</td>
</tr>
<tr>
<td>Low HDL (n=1004)</td>
<td>26.2</td>
<td>20.3</td>
<td>1.32 (1.15–1.52)</td>
<td>1.27 (1.10–1.46)</td>
<td>1.21 (1.04–1.40)</td>
<td>1.18 (1.02–1.37)</td>
</tr>
<tr>
<td>Elevated blood pressure (n=2917)</td>
<td>25.9</td>
<td>12.1</td>
<td>2.17 (1.83–2.57)</td>
<td>1.82 (1.53–2.16)</td>
<td>1.76 (1.48–2.10)</td>
<td>1.69 (1.42–2.01)</td>
</tr>
<tr>
<td>Elevated fasting glucose (n=1881)</td>
<td>24.1</td>
<td>19.8</td>
<td>1.20 (1.05–1.36)</td>
<td>1.14 (1.00–1.29)</td>
<td>1.06 (0.93–1.22)</td>
<td>1.06 (0.93–1.22)</td>
</tr>
</tbody>
</table>

HR indicates hazard ratio; CI, confidence interval; MetS, metabolic syndrome; CRP, C-reactive protein; IL-6, interleukin-6; CHF, congestive heart failure; CHD, coronary heart disease; LDL, low-density lipoprotein cholesterol.

*Model 1 adjusted for age, gender, race, field center, prevalent CHD, LDL, smoking, MetS (for CRP and IL-6), CRP ≥3 mg/L (for MetS, MetS components, and IL-6), IL-6 ≥2.21 pg/mL (for MetS, MetS components, and CRP), and incident CHD as a time-dependent covariate; Model 2 adjusted for Model 1 variables plus incident CHD as a time-dependent covariate and fasting insulin; Model 3 adjusted for Model 2 variables plus internal carotid IMT.

Results

Baseline characteristics of participants with and without MetS at baseline are shown in Table 1. Compared with subjects without MetS, subjects with MetS were more likely to be women, hypertensive, and have higher body mass index and waist circumference and worse lipid profiles. CRP, IL-6, insulin concentrations, and internal carotid IMT were also higher in the MetS group. Age, race, and smoking status were similar between the 2 groups.

There were 966 incident cases of CHF among the 4017 participants over a median follow-up of 12.2 years (incidence rate of 21.7 per 1000 person-years). Table 2 shows the HRs for incident CHF by baseline MetS, each MetS component and elevated CRP or IL-6 level. MetS, high waist circumference, low HDL, high blood pressure, and elevated CRP or IL-6 were each associated with incident CHF after adjustment for age, gender, race, field center, prevalent CHD, low-density lipoprotein cholesterol, smoking, and incident CHD.

When insulin level was added to the model, HRs were attenuated slightly for MetS, waist circumference, low HDL, and elevated blood pressure but not for CRP or IL-6. When internal carotid IMT was added to the model, HRs were slightly further attenuated. The association of waist circumference with CHF did not retain statistical significance with full adjustment.

MetS, Inflammation, and Incident CHF

Kaplan-Meier curves categorizing participants on the basis of MetS and CRP or IL-6 values are shown in the Figure.
Participants with both MetS and an elevated inflammation marker had a lower time free from CHF compared with participants with neither or either of MetS or an elevated inflammation marker (P < 0.001). Incidence rates and Cox proportional hazards models corresponding to this analysis of joint associations of MetS and an inflammation marker are shown in Table 3. The incidence of CHF ranged from 16.7 per 1000 person-years among those without MetS or elevated CRP to 31.1 per 1000 in those with MetS and elevated CRP. Rates were similar for MetS and IL-6. In adjusted analysis, compared with those with neither risk factor, presence of MetS without elevated CRP was associated with a 1.27-fold increased risk of CHF, whereas elevated CRP in the absence of MetS increased the risk 1.57-fold. With both factors together, this HR was 2.05 (95% CI, 1.73 to 2.43). Results were similar with IL-6, with corresponding HRs of 1.38, 1.59, and 1.95. The SI between MetS and CRP was 1.22 (95% CI, 0.56 to 1.88), indicating a 22% relative excess risk than expected under an additive model. The SI for IL-6 and MetS was 0.80 (95% CI, 0.40 to 1.20). The Spearman’s rank correlation coefficient between CRP and IL-6 was 0.48 (P < 0.001). When two inflammation markers, CRP and IL-6, were combined, subjects in whom both IL-6 and CRP were elevated had twice the risk of CHF compared with those in whom both IL-6 and CRP were not elevated (HR, 1.96; 95% CI, 1.62 to 2.36). The SI between CRP and IL-6 was 1.30 (95% CI, 0.49 to 2.11). There were no significant gender differences in associations of CRP or IL-6 and incident CHF.

### Inflammation-Incorporated MetS

To test whether the inclusion of CRP or IL-6 in the definition of MetS increased the predictive value of MetS for incident CHF, we created 2 new definitions of MetS: CRP-MetS and IL-6–MetS. The prevalence of CRP-MetS was 49.2% (1978 of 4017), with 442 of 2481 (17.8%) subjects without ATPIII MetS reclassified as CRP-MetS. CRP-MetS was associated with an adjusted HR of 1.58 (95% CI, 1.39 to 1.81) for CHF (Table 4). Compared with those without MetS by either definition, those subjects with newly reclassified CRP-MetS had an adjusted HR of CHF of 1.73 (95% CI, 1.41 to 2.11), which was similar to the HR of those with the MetS plus CRP-MetS (Table 5).

There were 1861 of 4017 subjects (46.3%) with IL6-MetS, with 325 of 2481 (13.1%) without the MetS by the ATPIII definition reclassified as IL-6–MetS. The adjusted HR of CHF in those with versus without IL-6–MetS was 1.61 (95% CI, 1.41 to 1.83, Table 4). Compared to those without MetS by either definition, those subjects with newly reclassified CRP-MetS had an adjusted HR of CHF of 1.73 (95% CI, 1.41 to 2.11), which was similar to the HR of those with the MetS plus CRP-MetS (Table 5).

### Figure

Time free from congestive heart failure based on MetS and inflammation status (A: CRP, B: IL-6). Solid black line indicates subjects with MetS and an elevated inflammation marker (A: CRP, B: IL-6). Solid gray line indicates subjects without MetS but with an elevated inflammation marker. Dashed line indicates subjects with MetS but without an inflammation marker. Dotted line indicates subjects with neither of them. MetS indicates metabolic syndrome; CRP, C-reactive protein; IL-6, interleukin-6.

### Table 3. Hazard Ratio of Incident CHF by the Combination of MetS and Elevated Inflammation Markers

<table>
<thead>
<tr>
<th>Elevated Inflammation Marker</th>
<th>MetS</th>
<th>Incidence Rate per 1000 Person-Years</th>
<th>N</th>
<th>Adjusted HR (95% CI) of CHF*</th>
<th>Incidence Rate per 1000 Person-Years</th>
<th>N</th>
<th>Adjusted HR (95% CI) of CHF*</th>
</tr>
</thead>
<tbody>
<tr>
<td>(−)</td>
<td>(−)</td>
<td>16.7</td>
<td>1695</td>
<td>1.00 (ref)</td>
<td>16.5</td>
<td>1899</td>
<td>1.00 (ref)</td>
</tr>
<tr>
<td>(−)</td>
<td>(+)</td>
<td>21.2</td>
<td>762</td>
<td>1.27 (1.06–1.53)</td>
<td>22.4</td>
<td>966</td>
<td>1.38 (1.17–1.62)</td>
</tr>
<tr>
<td>(+)</td>
<td>(−)</td>
<td>25.2</td>
<td>786</td>
<td>1.57 (1.32–1.88)</td>
<td>30.0</td>
<td>582</td>
<td>1.59 (1.32–1.92)</td>
</tr>
<tr>
<td>(+)</td>
<td>(+)</td>
<td>31.1</td>
<td>774</td>
<td>2.05 (1.73–2.43)</td>
<td>33.5</td>
<td>570</td>
<td>1.95 (1.63–2.34)</td>
</tr>
</tbody>
</table>

HR indicates hazard ratio; CI, confidence interval; CHF, congestive heart failure; MetS, metabolic syndrome.

*Adjusted for age, gender, race, field center, prevalent CHD, LDL, smoking, and incident CHD as a time-dependent covariate.
These studies, the HRs of MetS for incident CHF were ...

<table>
<thead>
<tr>
<th>MetS CRP-MetS IL-6-MetS</th>
</tr>
</thead>
<tbody>
<tr>
<td>No CRP-MetS 26.5 17.4 1.65 (1.45–1.87) 1.58 (1.39–1.81) 1.50 (1.30–1.73) 1.44 (1.25–1.66)‡</td>
</tr>
<tr>
<td>No IL-6-MetS 27.7 17.1 1.71 (1.50–1.94) 1.61 (1.41–1.83) 1.53 (1.33–1.76) 1.47 (1.28–1.69)</td>
</tr>
</tbody>
</table>

HR indicates hazard ratio; CI, confidence interval; CHF, congestive heart failure; MetS, metabolic syndrome; CHD, coronary heart disease; LDL, low-density lipoprotein cholesterol; IMT, intima-media thickness; IL-6, interleukin-6.

*Adjusted for age, gender, race, field center, prevalent CHD, LDL, smoking, and incident CHD as a time-dependent covariate.
†Adjusted for age, gender, race, field center, prevalent CHD, LDL, smoking, and incident CHD as a time-dependent covariate.
‡Adjusted for age, gender, race, field center, prevalent CHD, LDL, smoking, and incident CHD as a time-dependent covariate, fasting insulin level, and internal carotid IMT.
§CRP-MetS and IL6-MetS are defined as 3 or more of 6 components (5 components plus elevated CRP or IL-6, respectively).

In this study of older community-living adults, MetS was associated with development of CHF over a median of 12.2 years of follow-up. Using the inflammation markers CRP or IL-6 together with ATPIII defined MetS provided additive information to MetS in predicting incident CHF. Moreover, modified definitions of MetS that incorporated CRP or IL-6 detected more subjects at risk of CHF, based on a higher population attributable risk. Observed associations were independent of prevalent and incident CHD, insulin levels, and internal carotid IMT, a measure of subclinical vascular disease. To our knowledge, this is the first prospective study to evaluate the incorporation of inflammation markers into MetS definition with CHF as an outcome.

Three population-based studies have investigated the link between ATPIII defined MetS and incident CHF. In these studies, the HRs of MetS for incident CHF were ~1.5, similar to our findings. When each component of MetS was examined, abdominal obesity and high plasma glucose (≥110 mg/dL) were associated with incident CHF in the Multi-Ethnic Study of Atherosclerosis. In our study, low HDL and hypertension were associated with incident CHF. Differences in findings may relate to population ethnicity differences and the older age and much longer follow-up in CHS. Several other studies have also examined the effects of inflammation on the development of CHF. In the Health Aging and Body Composition study and the Framingham Heart study, CRP and IL-6 were both risk factors for CHF, but IL-6 had a stronger predictive value than CRP, unlike our findings. In the Rotterdam Study of older subjects, CRP was strongly and independently associated with incident CHF in men, but, unlike our findings the association was weak and not independent of other risk factors in women. In a previous CHS study, CRP in the highest quintile was associated with incident CHF over 5.5 years in the full cohort. In the current analysis with 12.2 years of follow-up, inflammation measured by either CRP or IL-6 was associated with incident CHF in nondiabetic men and women, and elevated levels of the 2 inflammation markers had similar HRs.

In this study, MetS and inflammation status provided additive predictive information, although SIs were not statistically significant. This finding is in keeping with a previous cross-sectional study of another cohort which showed that the presence of both CRP and insulin resistance was related to a history of heart failure. Further, higher population attributable risks for inflammation-modified definitions than in the ATPIII definition alone appeared to be due to a high population attributable risk of inflammation markers.

How MetS and inflammation are associated with incident CHF is uncertain. Our models were adjusted for baseline and

### Table 5. Hazard Ratios of Incident CHF Based on MetS and MetS With Inflammation Included as a Component (CRP-MetS and IL-6-MetS) *

<table>
<thead>
<tr>
<th>MetS</th>
<th>CRP-MetS</th>
<th>IL-6-MetS</th>
</tr>
</thead>
<tbody>
<tr>
<td>No CRP-MetS 26.5 17.4 1.65 (1.45–1.87) 1.58 (1.39–1.81) 1.50 (1.30–1.73) 1.44 (1.25–1.66)‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No IL-6-MetS 27.7 17.1 1.71 (1.50–1.94) 1.61 (1.41–1.83) 1.53 (1.33–1.76) 1.47 (1.28–1.69)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

HR indicates hazard ratio; CI, confidence interval; CHF, congestive heart failure; MetS, metabolic syndrome; CHD, coronary heart disease.

*CRP-MetS and IL6-MetS are defined as 3 or more of 6 components (5 components plus elevated CRP or IL-6, respectively).
†Adjusted for age, gender, race, field center, prevalent CHD, LDL, smoking, and incident CHD as a time-dependent covariate.
interval CHD events, carotid IMT, and insulin levels, suggesting that the associations were independent of atherosclerosis and hyperinsulinemia. One possible mechanism is that MetS and inflammation are associated with factors that lead to changes in the myocardium. It has been noted that markers of increased collagen production are associated with increased inflammation factors.57 Increased production of collagen in the heart can lead to a stiff noncompliant heart with resulting diastolic dysfunction and heart failure. Previous analyses of CHS has shown that approximately 50% of heart failure was associated with diastolic dysfunction.57 Another possible mechanism linking MetS, inflammation, and CHF are the activation of the renin-angiotensin system and the sympathetic nervous system. Activation of the renin-angiotensin system may inhibit the metabolic actions of insulin.44 Increased sympathetic tone increases peripheral vascular resistance.45

The strengths of this study include its prospective community-based design, large sample size, long follow-up, and large number of incident cases. All CHF cases were adjudicated by an expert panel, limiting the inclusion of false-positive cases. The careful adjudication of prebaseline and incident CHD events, and adjustment for carotid IMT allowed us to comprehensively evaluate whether observed associations were independent of atherosclerosis. Limitations of this study also merit consideration. First, categorization of continuous measures can result in misclassification of exposures such as inflammation and MetS. However, we believe that use of cut points recommended by the American Heart Association/ Centers for Disease Control and Prevention statement84 and the present definition of MetS15 is practical for clinical interpretation. Second, we only evaluated a single measurement of biomarkers at baseline. We believe that our large sample size compensated partly for this weakness. Last, for most participants with CHF we did not have echocardiogram data available on systolic function at the time of their diagnosis. This information would have allowed us to examine the differences in associations of inflammation-MetS with CHF with depressed systolic function and CHF with preserved systolic function.

Clinical Implications

In conclusion, in this study MetS and inflammation markers were each independently associated with risk of developing CHF. Incorporation of inflammation markers into the definition of ATPIII-defined MetS increased the number of people at risk for CHF and improved risk stratification for people at risk for CHF.

Acknowledgments

The authors thank the staff and participants in the Cardiovascular Health Study. A full list of participating CHS investigators and institutions can be found at http://www.chs-nhlbi.org. The authors also thank Josef Coresh, MD, PhD, for critical reading of the manuscript.

Sources of Funding

This research was supported by contracts N01-HC-35129, N01-HC-45133, N01-HC-75150, N01-HC-85079 through N01-HC-85086, N01 HC-15103, N01 HC-55222, and U01 HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke.

Disclosures

The sponsor involved in the design and conduct of the study and approval of the final manuscript.

References


Inflammation markers and the metabolic syndrome (MetS) are associated with risk of congestive heart failure. We evaluated whether combining inflammation markers and MetS provided additive information for predicting future heart failure (HF), and if incorporating inflammation markers to the MetS definition added prognostic information. We studied 4017 men and women ≥65 years old, without baseline HF or diabetes, participating in the Cardiovascular Health Study, an observational study with 12.2 years follow-up. Baseline “C-reactive protein (CRP)-MetS” or “interleukin-6 (IL-6)–MetS” were defined as presence of 3 of 6 components, with elevated CRP (≥3 mg/L) or IL-6 (≥2.21 pg/mL) as a sixth component added to ATPIII criteria. Cox models, adjusted for HF risk factors and incident coronary disease, were used to calculate HRs forHF. MetS and elevated inflammation markers were independently associated with HF risk (HRs, 95% CI: 1.32, 1.16 to 1.51 for MetS; 1.53, 1.34 to 1.75 for CRP; 1.37, 1.19 to 1.55 for IL-6). There was a 20% relative excess risk attributed to the combination of MetS and CRP (95% CI, 1.44 to 88%). CRP-MetS and IL-6–MetS definitions reclassified 18% and 13%, respectively, of participants as MetS. Both CRP-MetS and IL-6–MetS increased risk of HF by 60% compared with those without MetS. MetS and inflammation markers provided additive information on HF risk in this elderly cohort. Inflammation-incorporated MetS definitions identified more participants with the same risk level as ATPIII MetS. Considering inflammation markers and MetS together may be useful in clinical and research settings.
Metabolic Syndrome, Inflammation, and Incident Heart Failure in the Elderly: The Cardiovascular Health Study

Takeki Suzuki, Ronit Katz, Nancy Swords Jenny, Neil A. Zakai, Martin M. LeWinter, Joshua I. Barzilay and Mary Cushman

*Circ Heart Fail.* 2008;1:242-248; originally published online September 23, 2008; doi: 10.1161/CIRCHEARTFAILURE.108.785485

*Circulation: Heart Failure* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 1941-3289. Online ISSN: 1941-3297

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circheartfailure.ahajournals.org/content/1/4/242

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation: Heart Failure* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Circulation: Heart Failure* is online at:
http://circheartfailure.ahajournals.org//subscriptions/